NCT05229666

Brief Summary

Pregnancy ends in preterm birth (PTB) for approximately 1 in 10 women, though more often for Non-Hispanic Black women, 14.12% PTB rate, compared to 9.09% for Non-Hispanic White women. Psychosocial stress and childhood trauma each are associated with risk for PTB and PTB has an intergenerational impact: mothers born preterm are more likely to give birth preterm, especially amongst Black women. In this project, we will study mitochondria, which contain their own genome, the mitochondria DNA, and are inherited from the mother, as they represent a potential intersection point between psychosocial experiences and their biological embedding in underlying disease outcomes such as PTB

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
19mo left

Started Dec 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress74%
Dec 2021Dec 2027

Study Start

First participant enrolled

December 9, 2021

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 19, 2022

Completed
20 days until next milestone

First Posted

Study publicly available on registry

February 8, 2022

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

April 23, 2026

Status Verified

April 1, 2026

Enrollment Period

5 years

First QC Date

January 19, 2022

Last Update Submit

April 19, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Higher percentage of Black and Hispanic women in high stress group

    The high stress group is calculated using various measures including multiple psychosocial, life course, biological variables, and acute stress reactivity to a cognitive challenge (Stroop test).

    Prenatal

Secondary Outcomes (1)

  • Relatively earlier gestational age at birth in high stress group

    At birth

Study Arms (1)

Cognitive Challenge

OTHER
Other: Cognitive Challenge

Interventions

Cognitive challenge delivered via computer.

Cognitive Challenge

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Pregnant women 18 years of age or older (based on self-report)
  • Not currently smoking, drinking alcohol, or taking drugs (based on self-report)
  • Planning to deliver at CUIMC/NYP (based on self-report)
  • In the first or second trimester of pregnancy (prior to 28 weeks gestation) (based on self-report of estimated date of delivery)

You may not qualify if:

  • Multi-fetal pregnancy (based on self-report)
  • Taking medications regularly that affect the cardiovascular and inflammatory systems, including NSAIDS and other anti-inflammatories, α blockers, β blockers, corticosteroids, chronic-use asthma medications (e.g. beta2- adrenoceptor agonists) (based on self-report)
  • This does NOT include baby aspirin or low-dose aspirin, as baby aspirin / low-dose aspirin is not normally considered to be an NSAID.
  • Inflammatory conditions including rheumatoid arthritis, lupus, and multiple sclerosis (based on self-report)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Columbia University Irving Medical Center

New York, New York, 10032, United States

RECRUITING

MeSH Terms

Conditions

Premature BirthInflammation

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Catherine Monk, PhD

    Columbia University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Catherine Monk, PhD

CONTACT

Elizabeth Werner, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Diana Vagelos Professor of Women's Mental Health (in Obstetrics and Gynecology and Psychiatry)

Study Record Dates

First Submitted

January 19, 2022

First Posted

February 8, 2022

Study Start

December 9, 2021

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2027

Last Updated

April 23, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations